Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Abstract Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Antonio Martin-Bastida, Roberta J. Ward, Rexford Newbould, Paola Piccini, David Sharp, Christina Kabba, Maneesh C. Patel, Michael Spino, John Connelly, Fernando Tricta, Robert R. Crichton, David T. Dexter
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/447847d27a3f44eea2861e4c6d11074c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/447847d27a3f44eea2861e4c6d11074c

Documents similaires